Science · VL1 Joint Up
VL1 brings together a focused joint-support formula led by UC-II® undenatured type II collagen and Ovomet® eggshell membrane, alongside nutrients selected for connective tissue and bone-support nutrition.
We separate human clinical evidence from supporting or preclinical research, show the studied doses, and link to the original published papers so you can read beyond the headline.
01 · Lead actives
UC-II® and eggshell membrane have been evaluated in randomized controlled human trials. VL1 uses 40 mg of UC-II® and 300 mg of Ovomet® per serving—the same daily amounts used in several published studies of these ingredient categories.
Results vary by population, study design and outcome, so the evidence is best read as a body of research rather than a promise of a specific result for every person.
Randomized, double-blind, placebo-controlled studies in healthy adults with activity-related joint discomfort have evaluated 40 mg daily. Published trials reported improvements in selected knee range-of-motion and exercise-related joint outcomes.
Eggshell membrane has been studied in randomized controlled trials at 300 mg daily, with research examining joint comfort and daily function. Ovomet® is a branded eggshell membrane ingredient naturally containing structural components associated with connective tissue.
02 · How to read the evidence
Good science is specific. A result in one population or outcome should not be stretched into a universal claim.
03 · Researchers behind the papers
These researchers are cited because they authored relevant published work. Their inclusion does not mean they endorse VL1.
Distinguished Professor of Medicine and Rheumatology at UC Davis Health and a researcher in osteoarthritis, bone health and musculoskeletal aging. Dr. Lane co-authored a randomized controlled UC-II® knee osteoarthritis study.
Research citation only · No VL1 endorsement implied.
Professor of Exercise Physiology and Director of the Exercise Physiology Chair at UCAM in Spain. He co-authored randomized clinical research evaluating eggshell membrane and knee functionality.
Research citation only · No VL1 endorsement implied.
04 · Supporting formula
VL1 combines its lead actives with nutritional support for collagen formation, bones and a broader joint-focused routine.
Contributes to normal collagen formation for the normal function of cartilage and bones.
Vitamin D and vitamin K contribute to the maintenance of normal bones; vitamin D also supports normal muscle function.
Calcium is needed for maintenance of normal bones, while zinc contributes to normal protein synthesis and bone maintenance.
Included as supporting formula components. Research exists across these ingredient categories, but evidence strength and studied doses vary.
05 · References
Multicenter randomized, double-blind, placebo-controlled study; 96 adults; 40 mg/day for 24 weeks.
Randomized, double-blind, placebo-controlled study; 40 mg/day; exercise-related knee outcomes.
Multicenter randomized, double-blind, placebo-controlled comparative study.
Randomized, double-blind, placebo-controlled human study examining knee pain and daily-life function.
Randomized clinical trial assessing pain, function, strength and related outcomes.
A recent placebo-controlled study in knee osteoarthritis that did not find UC-II® superior to placebo at 24 weeks; included here for a balanced evidence view.
This page is educational and is not medical advice. Research on individual ingredients does not establish that VL1 prevents, treats or cures disease, and results from clinical studies may not apply to every person. If you have a medical condition, are pregnant, breastfeeding, taking medication or have food allergies, speak with a qualified healthcare professional before using supplements.